Bekaii-Saab, T., Lach, K., Hsu, L.-I., Siadak, M. F., Stecher, M., Ward, J., … Strickler, J. H. (2022). 376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes. In Annals of Oncology (Vol. 33, pp. S708–S708). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.514

Bekaii-Saab, T., K. Lach, L. -. I. Hsu, M. F. Siadak, M. Stecher, J. Ward, R. Beckerman, and J. H. Strickler. “376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes.” In Annals of Oncology, 33:S708–S708. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.514.

Bekaii-Saab T, Lach K, Hsu L-I, Siadak MF, Stecher M, Ward J, et al. 376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes. In: Annals of Oncology. Elsevier BV; 2022. p. S708–S708.

Bekaii-Saab, T., et al. “376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S708–S708. Crossref, doi:10.1016/j.annonc.2022.07.514.

Bekaii-Saab T, Lach K, Hsu L-I, Siadak MF, Stecher M, Ward J, Beckerman R, Strickler JH. 376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes. Annals of Oncology. Elsevier BV; 2022. p. S708–S708.